La Jolla Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LA JOLLA PHARMA
LA JOLLA PHARMA has one approved drug.
There are eleven US patents protecting LA JOLLA PHARMA drugs.
There are fifty-two patent family members on LA JOLLA PHARMA drugs in twenty-five countries.
Summary for La Jolla Pharma
| International Patents: | 52 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for La Jolla Pharma: | See patent lawsuits for La Jolla Pharma |
Drugs and US Patents for La Jolla Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| La Jolla Pharma | GIAPREZA | angiotensin ii acetate | SOLUTION;INTRAVENOUS | 209360-001 | Dec 21, 2017 | AP | RX | Yes | Yes | 9,572,856 | ⤷ Start Trial | ⤷ Start Trial | |||
| La Jolla Pharma | GIAPREZA | angiotensin ii acetate | SOLUTION;INTRAVENOUS | 209360-003 | Dec 23, 2021 | RX | Yes | Yes | 11,219,662 | ⤷ Start Trial | ⤷ Start Trial | ||||
| La Jolla Pharma | GIAPREZA | angiotensin ii acetate | SOLUTION;INTRAVENOUS | 209360-002 | Dec 21, 2017 | DISCN | Yes | No | 11,219,662 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for La Jolla Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2986308 | ⤷ Start Trial |
| South Korea | 20160117437 | ⤷ Start Trial |
| Poland | 3607962 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
